| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Entecavir |
| CAS number | 142217-69-4 |
| Molecular formula | C12H15N5O3 |
| Molecular weight | 277.28 |
| Appearance | White Powder |
| Purity | 99.0% |
| Description | Entecavir is a cyclopentyl guanosine analog launched for the once-daily oral treatment of chronic hepatitis B virus (HBV) infection, and it is the third nucleoside or nucleotide analog to be marketed for this indication. Lamivudine, a deoxythiacytosine analog, and adefovir dipivoxil, a nucleotide analog, have been marketed since 1998 and 2002, respectively. Entecavir and adefovir are specifically indicated for HBV, whereas lamivudine is indicated for both HBV and HIV infections. In mammalian cells, entecavir is efficiently phosphorylated to the active triphosphate form, which competes with the natural substrate deoxyguanosine triphosphate and functionally inhibits all three activities of the HBV polymerase: (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA.The most common adverse events associated with the use of entecavir are similar to those typically seen with HBV therapy and include headache, abdominal pain, diarrhea, fatigue, and dizziness. |
Entecavir is a new generation of guanine nucleoside analogue oral medicine for the treatment of hepatitis B virus infection. It is mainly used for the treatment of chronic type B with active viral replication and continuous increase in serum transaminase in adults, or active liver histology. Hepatitis is currently the fastest and strongest nucleoside analogue that reduces the virus and has the lowest mutation rate.
){kind=link}